<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02522585</url>
  </required_header>
  <id_info>
    <org_study_id>CIN-II p16 NK</org_study_id>
    <nct_id>NCT02522585</nct_id>
  </id_info>
  <brief_title>p16 and Ki-67 Stainings and Natural Killer (NK) Cells in CIN-II Management</brief_title>
  <official_title>Predictive Value of p16 and Ki-67 Immunohistochemical Staining and NK Cells in Expectant Management of Cervical Intraepithelial Neoplasia Grade 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Parc de Salut Mar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Parc de Salut Mar</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the outcome of cervical intraepithelial neoplasia
      grade 2 (CIN-II) patients followed up without treatment for 24 months according to p16 and
      ki-67 immunohistochemical staining and to the expression of NK cell receptors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cervical cancer and its precursor lesions, cervical intraepithelial neoplasia (CIN),
      represents a significant public health problem,induced by persistent infection of human
      papillomavirus (HPV). It is known that a significant percentage of CIN regresses
      spontaneously and only a minority of these lesions progress to cervical cancer. CIN-II is an
      intermediate state that can regress to CIN-I or less, or progress to CIN-III spontaneously.
      The rate of spontaneous regression and progression in follow-up studies are around 40-60% and
      10-20%, respectively. Overestimating CIN-II lesions may cause overtreatment by excisional
      treatment and increase the risk of subsequent obstetric complications.

      Patients newly diagnosed with CIN-II colposcopy-directed biopsy who agreed to follow up at
      four months intervals for at least 12 months with cervical cytology and colposcopy, were
      prospectively recruited. p16, ki-67 and NK receptors expression were analyzed in all CIN-II
      biopsies. Total regression, partial regression, persistence and progression rates of CIN-II
      were defined as a final outcome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Status of cervix pathology using cervical smear test (CIN grade)</measure>
    <time_frame>2 years</time_frame>
    <description>Cervical cytology test and colposcopy every 4 months starting with diagnose CIN-II or CIN-III means presence of lesion, CIN-I is regression of the lesion, and Negative is abscence of lesion.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Conservative management</arm_group_label>
    <description>Patients diagnosed of CIN-II by directed biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conservative management</intervention_name>
    <description>Control of CIN-II with cytology and colposcopy to try to avoid unnecessary surgery</description>
    <arm_group_label>Conservative management</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Citologies and biopsies of the cervix. Blood cells.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult females with CIN-II lesion on cervical biopsy that agree to a conservative management
        during a period not more than 24 months, referred to the low genital tract diseases clinic
        of Hospital del Mar.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  preferred expectant management than immediate treatment

          -  exocervical histological diagnosis of CIN-II

          -  lesion completely visualized by colposcopy

          -  entire squamocolumnar junction of the cervix was visible

          -  showing no evidence of any immunodeficiency disease

          -  no history of previous cervical treatment

          -  could be followed-up every four months during one year

          -  signed consent form

        Exclusion Criteria:

          -  not coming to follow up appointments
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gemma Mancebo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parc de Salut Mar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramon Carreras, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Parc de Salut Mar</affiliation>
  </overall_official>
  <reference>
    <citation>Discacciati MG, de Souza CA, d'Otavianno MG, Ângelo-Andrade LA, Westin MC, Rabelo-Santos SH, Zeferino LC. Outcome of expectant management of cervical intraepithelial neoplasia grade 2 in women followed for 12 months. Eur J Obstet Gynecol Reprod Biol. 2011 Apr;155(2):204-8. doi: 10.1016/j.ejogrb.2010.12.002. Epub 2010 Dec 28.</citation>
    <PMID>21193261</PMID>
  </reference>
  <reference>
    <citation>Tsoumpou I, Arbyn M, Kyrgiou M, Wentzensen N, Koliopoulos G, Martin-Hirsch P, Malamou-Mitsi V, Paraskevaidis E. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev. 2009 May;35(3):210-20. doi: 10.1016/j.ctrv.2008.10.005. Epub 2009 Mar 3. Review.</citation>
    <PMID>19261387</PMID>
  </reference>
  <reference>
    <citation>del Pino M, Garcia S, Fusté V, Alonso I, Fusté P, Torné A, Ordi J. Value of p16(INK4a) as a marker of progression/regression in cervical intraepithelial neoplasia grade 1. Am J Obstet Gynecol. 2009 Nov;201(5):488.e1-7. doi: 10.1016/j.ajog.2009.05.046. Epub 2009 Aug 15.</citation>
    <PMID>19683687</PMID>
  </reference>
  <reference>
    <citation>Galgano MT, Castle PE, Atkins KA, Brix WK, Nassau SR, Stoler MH. Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol. 2010 Aug;34(8):1077-87. doi: 10.1097/PAS.0b013e3181e8b2c4.</citation>
    <PMID>20661011</PMID>
  </reference>
  <reference>
    <citation>Guedes AC, Brenna SM, Coelho SA, Martinez EZ, Syrjänen KJ, Zeferino LC. p16(INK4a) Expression does not predict the outcome of cervical intraepithelial neoplasia grade 2. Int J Gynecol Cancer. 2007 Sep-Oct;17(5):1099-103. Epub 2007 Mar 15.</citation>
    <PMID>17367324</PMID>
  </reference>
  <reference>
    <citation>McAllum B, Sykes PH, Sadler L, Macnab H, Simcock BJ, Mekhail AK. Is the treatment of CIN 2 always necessary in women under 25 years old? Am J Obstet Gynecol. 2011 Nov;205(5):478.e1-7. doi: 10.1016/j.ajog.2011.06.069. Epub 2011 Jun 25.</citation>
    <PMID>21872201</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2015</study_first_submitted>
  <study_first_submitted_qc>August 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2015</study_first_posted>
  <last_update_submitted>April 19, 2016</last_update_submitted>
  <last_update_submitted_qc>April 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Parc de Salut Mar</investigator_affiliation>
    <investigator_full_name>Jordi Genoves</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>expectant management</keyword>
  <keyword>p16</keyword>
  <keyword>immunohistochemistry</keyword>
  <keyword>regression</keyword>
  <keyword>progression</keyword>
  <keyword>cervical intraepithelial neoplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

